Research and Markets: Systemic Lupus Erythematosus - Benlysta Approval Brings Lessons and Hope to Market - Immunomedics/UC

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Product Profiles: Systemic Lupus Erythematosus - Benlysta Approval Brings Lessons and Hope to Market" report to their offering.

Datamonitor surveyed 108 rheumatologists in the US in the wake of Benlysta's approval, gauging current perceptions of the drug and the clinical impact that it will have. Lessons learned from the clinical trial program of Benlysta are already being applied to additional drug candidates, and large-scale international trials are becoming the norm.

Features and benefits

  • Access Datamonitor's independent clinical and commercial assessment of off-label, marketed, and pipeline candidates for systemic lupus erythematosus.
  • Review findings from Datamonitor's survey of 108 US rheumatologists following Benlysta's March 2011 FDA approval.
  • Understand where Benlysta will be positioned in the market and which pipeline candidates pose the greatest competitive threat.
  • Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.


On March 9, 2011, Benlysta became the first FDA approved treatment for systemic lupus erythematosus (SLE) in over 50 years. Datamonitor's primary research of over 100 rheumatologists in the US reveals physician perception of the drug following its approval. Following on from data on rheumatoid arthritis, Eli Lilly moved LY2127399 into Phase III for SLE in December 2010. Eli Lilly's risky move could pay off if successful, as potential advantages over Benlysta, including the drug's subcutaneous formulation, would lead to commercial success if it reaches the market.

Several promising drug candidates remain in the late-stage pipeline for SLE. Immunomedics/UCB's epratuzumab moved into Phase III in December 2010. If successful, it could reach the market as early as 2015. ImmuPharma/Cephalon's Lupuzor remains in Phase IIb, but positive data from an earlier trial have left rheumatologists eager to see more.

Your key questions answered

  • How do rheumatologists in the US view Benlysta following its FDA approval?
  • How have late-stage clinical trial programs been influenced by the Phase III success of Benlysta?
  • Which late stage pipeline candidates offer the most promise for treating SLE, and how do they address unmet needs?
  • How do novel pipeline agents compare to current off-label treatment options?

Key Topics Covered:

  • Approved: Benlysta (belimumab; Human Genome Sciences/GlaxoSmithKline)
  • Physician perception of Benlysta
  • Clinical and commercial attractiveness
  • Off-label: Rituxan/MabThera (rituximab; Biogen Idec/Roche/Zenyaku Kogyo)
  • Clinical and commercial attractiveness
  • Off-label: CellCept (mycophenolate mofetil; Roche/Vifor Pharma)
  • Clinical and commercial attractiveness
  • Off-label: Orencia (abatacept; Bristol-Myers Squibb)
  • Clinical and commercial attractiveness
  • Atacicept (Merck Serono/Bristol-Myers Squibb)
  • Clinical and commercial attractiveness
  • Epratuzumab (Immunomedics/UCB)
  • Drug profile
  • Development overview
  • SWOT analysis
  • Clinical and commercial attractiveness
  • Lupuzor (forigerimod; ImmuPharma/Cephalon/SymBio Pharmaceuticals)
  • Drug profile
  • Development overview
  • SWOT analysis
  • Clinical and commercial attractiveness
  • LY2127399 (Eli Lilly)
  • Clinical and commercial attractiveness
  • Other drugs in development for systemic lupus erythematosus
  • A-623 (Anthera Pharmaceuticals)
  • Laquinimod (Teva/Active Biotech)
  • Paquinimod (57-57, ABR-215757; Active Biotech)

For more information visit

Source: Datamonitor


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.